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ABSTRACT 
Background: Decreases in circulating neutrophils (polymorphonuclear leukocytes, PMNs) 
have been reported in patients treated with the anti-interleukin-6 receptor (IL-6R) antibody 
tocilizumab (TCZ); the mechanism for this is unclear. We hypothesize that TCZ reduces 
circulating neutrophils by affecting margination and / or bone marrow trafficking without 
affecting neutrophil function or apoptosis. 
Materials and methods: 18 healthy subjects were randomized to single intravenous dose of 
TCZ 8 mg/kg (n = 12) r placebo (n = 6) on day 0. On day 4, each subject had autologous 
indium-111-labeled neutrophils re-injected, and their kinetics quantified with longitudinal 
profiling in a whole body gamma-counter. TCZ-treated subjects were divided into two groups 
according to the extent of reduction in neutrophil count. 
Results: Mean day 4 neutrophil counts, as % baseline, were 101.9%, 68.3% and 44.2% in the 
placebo, TCZ-PMN-‘high’ and TCZ-PMN-‘low’ groups, respectively (p < 0.001). Following 
TCZ, neutrophil function, activation and apoptosis ex vivo were all unaffected. In vivo, there 
were no differences in early blood recovery or margination to liver / spleen and bone marrow; 
however, later neutrophil re-distribution to bone marrow was markedly reduced in the TCZ-
PMN-low group (peak pelvic count as % day 4 count on: day 5, 188% placebo vs 127% TCZ-
PMN-low, p < 0.001; day 10, 180% placebo vs 132% TCZ-PMN-low, p < 0.01), with a trend 
towards higher liver / spleen neutrophil retention. 
Conclusions: We have demonstrated for the first time in humans that IL-6R blockade affects 
neutrophil trafficking to the bone marrow without influencing neutrophil functional capacity. 
 
Key words: neutrophil; interleukin-6; tocilizumab; trafficking 
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INTRODUCTION 
Interleukin-6 (IL-6) is a pleiotropic cytokine with a central role in the pathogenesis of a 
number of inflammatory and autoimmune disorders [1]. Neutrophils (polymorphonuclear 
leukocytes, PMNs) are involved in many inflammatory diseases, in part through the release 
of cytokines and chemokines, and through antigen presentation [2]. Activated neutrophils are 
a source of soluble interleukin-6 receptor (sIL-6R), initiating ‘trans-signaling’ in cell types 
that do not express membrane-bound IL-6R (mIL-6R), thus driving chronic inflammation [3-
5].  
 
Tocilizumab (TCZ), a humanized monoclonal antibody against both forms of the IL-6R, is 
licensed for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis and 
polyarticular juvenile idiopathic arthritis [6-8]. Decreases in circulating neutrophil levels 
have been reported after initiation of TCZ in clinical trials. Despite this, the rate of serious 
infections is low (4.7 per 100 patient-years) [9] and no temporal association has been 
described between decreased neutrophil counts and the occurrence of such infections [6-10]. 
 
Data from animal studies on the effects of IL-6 on neutrophil function have, to date, been 
inconsistent. IL-6 administration in rabbits results in reduced expression of surface CD62L 
on circulating and bone marrow neutrophils [11]. IL-6 administration in monkeys, however, 
results in reduced expression of CD162 whilst CD11b and CD62L expression is unchanged; 
this process is inhibited by TCZ [12]. In humans, in vitro exposure of healthy neutrophils to 
IL-6 does not affect neutrophil survival or functional capacity [13], although additional 
lipopolysaccharide (LPS) stimulation following TCZ exposure in vitro has been reported to 
result in differences in oxidative burst and phagocytic capacity under hypoxic conditions 
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[14]. Studies on neutrophils isolated from patients with rheumatoid arthritis 28 days after 
administration of TCZ, however, show no effect on neutrophil function or apoptosis [13]. 
 
Administration of recombinant human IL-6 in rats [15] and rabbits [16] results in a biphasic 
blood neutrophilia, with an early peak resulting from leukocyte mobilization from the 
intravascular marginated pool, and a late peak due to neutrophil release from the post-mitotic 
bone marrow pool. IL-6 contributes to granulopoiesis in granulocyte colony-stimulating 
factor (G-CSF)- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-deficient 
mice [17]. In humans, strenuous exercise similarly causes a biphasic neutrophilia [18] that 
has been shown to correlate with an increase in serum IL-6 [19], although this correlation has 
not been replicated in all studies [20]. 
 
Broader aspects of neutrophil function and apoptosis at the expected neutrophil nadir 4 days 
following TCZ administration have not been assessed, and no studies have been undertaken 
to examine the effects of IL-6 modulation on in vivo whole body neutrophil kinetics in 
humans. Likewise, to date there is no mechanistic understanding of the decrease in 
circulating neutrophils following treatment with TCZ. Such data are also required to comply 
with European Medicines Agency requests on providing further safety information on the use 
of TCZ. Therefore, an exploratory study was conducted in healthy subjects to investigate the 
hypothesis that IL-6R blockade affects whole body neutrophil kinetics by affecting neutrophil 
margination and / or re-uptake by the bone marrow, without affecting neutrophil function and 
survival. 
 
METHODS 
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Study subjects  
This single-blind, randomized study (ClinicalTrials.gov identifier NCT01991990) enrolled 
healthy male subjects aged 18-65 years. Subjects had a body mass index between 18 kg/m
2
 
and 30 kg/m
2
, were non-smokers, and did not receive any medication other than paracetamol. 
The study was approved by the East Midlands Nottingham Research Ethics Committee 
(Reference 13/EM/0350). All subjects provided written informed consent in accordance with 
the Declaration of Helsinki and local laws and regulations. 
 
Study design 
Subjects were randomized to receive a single intravenous dose, blinded to subjects only, of 
TCZ 8 mg/kg or saline placebo (2:1 randomization) on day 0 (Figure 1A). No subjects 
experienced clinically significant Common Terminology Criteria (CTC) grade 3 or 4 
neutropenia (neutrophil count below 1 × 10
9
/L). However, there was a wide variation in the 
relative reduction in blood neutrophil count following TCZ; therefore in the analysis TCZ-
treated subjects were divided into two equal-sized groups to examine the effects of IL-6R 
blockade based on the extent of the decrease in their neutrophil count. This grouping was 
result-driven and not pre-defined. 
 
Neutrophil isolation  
Neutrophils were isolated from peripheral blood using dextran sedimentation and 
discontinuous plasma-Percoll (Fisher Scientific, Loughborough, UK) gradient centrifugation, 
as previously described [21].
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Neutrophil function and apoptosis ex vivo  
Neutrophil function and apoptosis were assessed ex vivo on day 0 (pre-dose) and day 4 (post-
dose). Respiratory burst was measured in neutrophils, primed with tumor necrosis factor-
alpha (TNFα, 20 ng/mL; R&D, UK) or phosphate-buffered saline (PBS) control for 30 
minutes, as the peak in N-formyl-methionyl-leucyl-phenylalanine (fMLP; Sigma-Aldrich, 
UK)-stimulated, horseradish peroxidase (HRP; Sigma-Aldrich, UK)-catalyzed luminol 
(Sigma-Aldrich, UK) chemiluminescence [22]. Phagocytosis was assessed in neutrophils 
equilibrated at 4°C or 37°C for 1 hour followed by addition of heat-killed, eFluor670 
(eBioscience, UK)-labeled Streptococcus pneumoniae (ratio 1 PMN : 29 S. pneumoniae) for 
1 hour, and quantified by flow cytometry [23]. 
 
For assessment of apoptosis, neutrophils were incubated for 20 hours with vehicle control or 
a pro-survival factor, either GM-CSF (1 ng/mL; R&D, UK) or TNFα (20 ng/mL), and 
apoptosis was quantified by annexin V-FITC and propidium iodide (PI) (BD Biosciences, 
UK) staining, with early apoptotic cells being annexin V
+
/PI
-
 and late apoptotic cells annexin 
V
+
/PI
+
. Cytospin slides were also generated and stained with Diff-Quik staining (Gamidor, 
UK), and neutrophil morphology examined in a minimum of 300 neutrophils per slide using 
oil immersion light microscopy with the assessor blinded to treatment conditions. Apoptotic 
cells were identified by their darkly stained, pyknotic nuclei [24]. 
 
Surface markers were measured in fresh (0 min), PBS control (30 min) and fMLP-stimulated 
(30 min) neutrophils incubated for 30 minutes with the anti-human antibodies CD11b-
BV421, CD16-FITC, CD62L-APC and CD162-PE, or isotype controls (BD Biosciences, 
UK). Expressions were quantified as median fluorescence intensities (MFI) by flow 
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cytometry. Shape change was assessed by median forward scatter (FSC). Data were analyzed 
using FlowJo software. 
 
Neutrophil kinetics in vivo  
Autologous neutrophils were isolated from peripheral blood by Hetastarch (Grifols, UK) 
sedimentation and discontinuous plasma-Percoll gradient centrifugation. Neutrophils were 
harvested and labeled with indium-111 (
111
In; Mallinckrodt, UK) chelated to tropolone 
(Ipswich Pharmacy Manufacturing Unit, UK) by incubation at room temperature for 10 
minutes, subsequently washed twice in platelet-poor plasma and re-injected (maximum 2.5 
MBq) into the subjects [25,26]. 
 
Blood was sampled 45 minutes post re-injection to determine the percentage recovery of 
radiolabeled neutrophils, as previously described [26]. Longitudinal whole body profiles were 
generated in a fully shielded whole body gamma-counter at 45 minutes (day 4), 1 day (day 5) 
and 6 days (day 10) following re-injection. For each scan, the collimated anterior and 
posterior detectors moved from head downwards at 14 cm/min for 10 minutes (Figure 5A). 
Counts were background and decay corrected, and geometric means normalized to day 4 
counts. 
 
Safety 
Safety was assessed by physical examination, vital signs, and monitoring of adverse events 
and laboratory parameters. All subjects completed all study and safety visits. 
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Statistical analysis 
All ex vivo assays were performed in triplicate. Data are presented as mean ± SEM of (n) 
independent experiments, and analyzed using GraphPad Prism version 6. Treatment groups 
were compared using one-way ANOVA and unpaired t-tests with Holm-Sidak correction for 
multiple comparisons. 
 
RESULTS 
Study subjects 
A total of 18 subjects were treated with a single intravenous dose of TCZ 8 mg/kg (n = 12) or 
saline placebo (n = 6) on day 0. There was a significant reduction in day 4 neutrophil count in 
TCZ-treated (p < 0.001) but not placebo-treated subjects (Figure 1B-C). In the TCZ-treated 
subjects, splitting the groups evenly resulted in 6 subjects with < 51.3% relative reduction in 
day 4 neutrophil count (TCZ-PMN-‘high’ group) and 6 subjects with > 51.3% relative 
reduction in day 4 neutrophil count (TCZ-PMN-‘low’ group). No subjects experienced CTC 
grade 3 or 4 neutropenia. Mean neutrophil counts at day 4 as % baseline were 101.9% in the 
placebo group, 68.3% in the TCZ-PMN-high group, and 44.2% in the TCZ-PMN-low group 
(p < 0.001; Figure 1D). 
 
Neutrophil function and apoptosis ex vivo 
Respiratory burst activity was intact at days 0 and 4 in neutrophils isolated from placebo, 
TCZ-PMN-low, and TCZ-PMN-high groups; mean peak chemiluminescence did not show 
statistically significant differences between the unprimed groups, or between the TNFα-
primed groups (Figure 2A,D-E). Rates of phagocytosis of heat-killed S. pneumoniae were 
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also similar in all groups, indicating intact phagocytic activity (Figure 2B-C,F-G). Neutrophil 
survival following 20 hours of ex vivo culture was unaffected by TCZ, with apoptosis rates 
showing no differences between placebo and TCZ groups under either untreated conditions or 
in the presence of the pro-survival factors GM-CSF or TNFα (Figure 3). Cell surface markers 
of neutrophil activation, including CD11b, CD62L, CD162, and shape change [27-29], were 
likewise unaffected by TCZ in both control and fMLP-stimulated neutrophils (Figure 4A-
B,D-G). Expression of CD16, a marker expressed on mature neutrophils, and declines on 
aging neutrophils [30], was also unaffected by TCZ (Figure 4A,C). 
 
Neutrophil kinetics in vivo 
For analysis of the in vivo kinetic data, one subject from the TCZ-PMN-high group was 
excluded because of external (skin) contamination, which affected the profiling data. The 
mean (SEM) 45-minute blood recovery values of 
111
In-labeled neutrophils at day 4 as % total 
body count were 26.7 (4.7) in the placebo group (n = 6), 28.4 (2.5) in the TCZ-PMN-high 
group (n = 5) and 29.9 (5.9) in the TCZ-PMN-low group (n = 6) (Figure 5B); these were not 
significantly different, indicating a similar extent of early neutrophil intravascular 
margination in all groups. Consistent with these data, in TCZ-treated subjects, there were no 
differences in the distribution of radiolabeled neutrophils in the liver / spleen or pelvic 
marrow pools 45 minutes post re-injection (Figure 5C-D). These data indicate again that the 
kinetics of early neutrophil margination are unaffected following TCZ. 
 
However, neutrophil re-distribution to, and uptake in, the pelvic marrow region (which could 
be used as an index of generalized bone marrow activity) on days 5 and 10 (1 and 6 days 
following 
111
In-labeled neutrophil re-injection, respectively) was considerably lower in the 
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TCZ-PMN-low group (Figure 5E-F); peak pelvic count, as % day 4 count, on day 5 was 
188% in the placebo group, 171% in the TCZ-PMN-high group, and 127% in the TCZ-PMN-
low group (p < 0.001, placebo vs TCZ-PMN-low), whereas on day 10, it was 180% in the 
placebo group, 168% in the TCZ-PMN-high group, and 132% in the TCZ-PMN-low group (p 
< 0.01, placebo vs TCZ-PMN-low) (Figure 5H). This was associated with a clear trend 
towards higher neutrophil retention in the liver / spleen on days 5 and 10 in the TCZ-PMN-
low group (Figure 5G), and a correlation between day 10 liver / spleen peak radioactivity and 
day 4 neutrophil count (r
2
 = 0.38, p < 0.05; Figure S1C). 
 
Safety 
There were no adverse events leading to study withdrawal. Overall, 8 subjects experienced 12 
adverse events, and all resolved without sequelae (Table S1). Of the 9 adverse events in the 
TCZ-treated subjects, all were mild or moderate in severity and were consistent with the 
known safety profile of TCZ. 
 
DISCUSSION  
Anti-IL-6R therapy is an important intervention in inflammatory diseases, and has been used 
successfully in diseases such as rheumatoid arthritis [8,31]. However, concerns have been 
raised about its effects on circulating neutrophil numbers and function. This study is the first 
to assess the pharmacodynamic effects of anti-IL-6R on human neutrophil kinetics in vivo 
and the first to comprehensively investigate the effects of IL-6R blockade on neutrophil 
function and apoptosis ex vivo at the expected nadir of blood neutrophil count.  
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Results of this exploratory study in healthy subjects demonstrated a reduction in neutrophil 
count 4 days after administration of intravenous TCZ, representing the previously defined 
neutrophil nadir following TCZ administration [32]. Neutrophil respiratory burst and 
phagocytic activity remained intact at day 4, suggesting that the capacity of circulating 
neutrophils to respond to pathogens was unaffected at the time point when TCZ has its 
greatest effect on the numbers of circulating neutrophils. These data support the clinical trial 
experience of TCZ use in that no temporal relationship has been demonstrated between 
reductions in neutrophil counts and risks of serious infection [6-10,33]. 
 
Neutrophils were not activated at baseline after TCZ infusion and responded to ex vivo fMLP 
activation to a similar degree to neutrophils from placebo subjects. Rates of apoptosis in ex 
vivo culture were also unaffected, suggesting that TCZ does not affect the survival of 
circulating neutrophils, whose half-life has been estimated in other ex vivo and in vivo 
labeling studies ranging from several hours to 3.8 days [34-36]. The systemic administration 
of TCZ makes differential functional effects on neutrophils in the circulating and marginated 
pools unlikely. The current results are consistent with a recent study in healthy subjects and 
patients with rheumatoid arthritis, which showed no effect of TCZ on ex vivo neutrophil 
function and rates of apoptosis, when measured 4 and 12 weeks after multiple doses of TCZ 
[13]. 
 
Assessment of whole body kinetics showed that early neutrophil margination was unaffected 
by TCZ, with no difference in neutrophil distribution in the blood, liver / spleen and pelvic 
marrow regions 45 minutes following re-injection of radiolabeled neutrophils. However, 
neutrophil trafficking at later times was significantly different in the TCZ-PMN-low group, 
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as demonstrated by reduced neutrophil re-uptake to the pelvic marrow region, with a trend 
towards higher neutrophil retention in the liver / spleen region on days 5 and 10. These 
findings indicate that TCZ treatment reduces bone marrow re-uptake of neutrophils, either 
directly, or indirectly via a mechanism involving enhanced retention by the liver and spleen. 
The former mechanism would be consistent with the previously defined role of IL-6 in the 
release of neutrophils from the bone marrow compartment in animal models [15,16]. No 
subjects experienced CTC grade 3 or 4 neutropenia. However, the significant relative 
reduction in neutrophil count in TCZ-treated subjects and the differences in neutrophil 
kinetics in the TCZ-PMN-low group demonstrate the biological effects of TCZ even in the 
absence of clinically significant neutropenia. 
 
The study has several limitations. The control subjects in our study received saline placebo 
rather than irrelevant immunoglobulin G (IgG). Previous studies have shown that IL-6-
induced STAT-3 phosphorylation is effectively blocked by TCZ but not by IgG in 
neutrophils from healthy subjects [13]; nevertheless, we cannot rule out the possibility of 
non-specific IgG effects on neutrophils in our results. 
 
Neutrophil release from the bone marrow was not directly examined in the current model, 
and as such, the effects of TCZ on the release of neutrophils from the bone marrow post-
mitotic pool in response to a stimulus were not formally assessed. Further investigation is 
required to demonstrate definitively whether IL-6R blockade affects neutrophil de-
margination and / or release of these cells from the bone marrow. 
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The 45-minute blood recovery values of 
111
In-labeled neutrophils in the current study were 
slightly lower than previously demonstrated values. This can indicate a degree of cellular 
damage during the isolation and radiolabeling process. However, there was no evidence of 
abnormally high margination of radiolabeled neutrophils to the liver / spleen in the placebo or 
TCZ groups, which would be observed in the case of cellular damage. In addition, it has been 
demonstrated previously that the current method of neutrophil isolation and radiolabeling 
does not cause ex vivo priming or activation of neutrophils, hence allowing neutrophil 
kinetics to be studied under physiological conditions [26]. 
 
The whole body profiling data demonstrated the effects of TCZ treatment on neutrophil 
kinetics in vivo, suggesting reduced neutrophil re-uptake to the pelvic bone marrow and some 
evidence of persistent retention of neutrophils in the liver / spleen either through a failure of 
de-margination or enhanced neutrophil destruction at these sites. In humans healthy 
neutrophils are removed from the circulation in approximately equal proportions in the liver, 
spleen and bone marrow. This occurs in a seemingly random and age-independent fashion, 
and does not reflect intravascular apoptosis, which in health is extremely rare. This situation 
contrasts somewhat to the mouse where aged neutrophils are preferentially removed by the 
bone marrow and this involves up-regulation of CXCR4 [37]. Following removal from the 
circulation neutrophils then undergo apoptosis and are efferocytosed by splenic marginal 
zone and bone marrow stromal macrophages; this later process has been shown to regulate 
blood neutrophil levels via the production of G-CSF [38,39]. While the role of the IL-6/IL-6R 
axis in these processes is uncertain, marrow sampling was not part of our study. 
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Overall, these data suggest that the reduction in circulating neutrophils results in a relative 
rather than absolute neutropenia in patients treated with TCZ. This observation may help 
explain why no temporal relationship between CTC grade 3 or 4 neutropenia and serious 
infection has been observed with TCZ treatment. Further work exploring the release of 
neutrophils from the bone marrow in the presence of TCZ is warranted. 
 
In summary, we have demonstrated for the first time in humans that IL-6R blockade by a 
single intravenous dose of tocilizumab affects in vivo neutrophil trafficking to the bone 
marrow without influencing the ex vivo functional capacity, activation and apoptosis of these 
cells. 
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Figure 1. Effect of intravenous TCZ administration on blood neutrophil count. (A) 
Study design. (B-C) Day 0 (pre-dose) and day 4 (post-dose) blood neutrophil counts in 
placebo-treated subjects (n = 6) and TCZ-treated subjects (n = 12). # p < 0.001. (D) Day 4 
neutrophil count, as % day 0 count, in placebo (n = 6), TCZ-PMN-high (n = 6) and TCZ-
PMN-low (n = 6) groups. * p < 0.05, # p < 0.001 vs placebo; # p < 0.001 across three groups. 
Data shown as mean ± SEM. 
 
Figure 2. Ex vivo neutrophil respiratory burst and phagocytic capacity following TCZ. 
(A) Representative results of respiratory burst measurement by luminol-HRP 
chemiluminescence. RLU, relative light units. (B) Representative flow cytometry results 
demonstrating phagocytosis as S. pn umoniae-eFluor670 fluorescence. (C) Light microscopy 
example of a neutrophil containing phagocytosed S. pneumoniae (arrow). Original 
magnification ×100. (D-E) Respiratory burst activity, quantified as (D) absolute and (E) 
relative peak chemiluminescence, in unprimed (a) and TNFα-primed (b) neutrophils. * p < 
0.05, † p < 0.01, # p < 0.001 vs a; ns, non-significant across treatment groups (a and b). (F-G) 
Phagocytosis of heat-killed eFluor670-labeled S. pneumoniae, quantified as (F) MFI and (G) 
% eFluor670-positive neutrophils, in neutrophil only (a), 4°C (b) and 37°C (c) treatment 
groups. # p < 0.001 vs b; ns, non-significant across treatment groups (c). Placebo, n = 6; 
TCZ-PMN-high, n = 6; TCZ-PMN-low, n = 6. Data shown as mean ± SEM. 
 
Figure 3. Ex vivo neutrophil apoptosis following TCZ. (A) Representative flow cytometry 
plots of neutrophils following 20 hours of culture showing annexin V and PI staining. (B) 
Light microscopy example of viable (black arrow) and apoptotic (red arrows) neutrophils. 
Original magnification ×100. (C-D) Apoptosis following 20 hours of culture, quantified as 
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(C) % annexin V-positive cells by flow cytometry and (D) % apoptotic cells by microscopic 
morphology, under untreated (a), GM-CSF-treated (b) and TNFα-treated (c) conditions. * p < 
0.05, † p < 0.01, # p < 0.001 vs a; ns, non-significant across treatment groups (a, b and c). 
Placebo, n = 6; TCZ-PMN-high, n = 6; TCZ-PMN-low, n = 6. Data shown as mean ± SEM. 
 
Figure 4. Ex vivo neutrophil activation following TCZ. (A) Representative flow cytometry 
plots of CD11b, CD16, CD62L, CD162 and forward scatter (FSC) in neutrophils stimulated 
with fMLP ex vivo. (B-G) Flow cytometry quantification of surface markers of activation, 
including (B) CD11b MFI, (C) CD16 MFI, (D) CD62L MFI, (E) CD162 MFI, and shape 
change, including (F) forward scatter and (G) % shape changed cells, at 0 minute control (a), 
30 minute control (b) and 30 minute fMLP (c). * p < 0.05, # p < 0.001 vs a; ns, non-
significant across treatment groups (a and c). Placebo, n = 6; TCZ-PMN-high, n = 6; TCZ-
PMN-low, n = 6. Data shown as mean ± SEM. 
 
Figure 5. In vivo whole body neutrophil kinetics following TCZ. (A) Schematic of whole 
body profiling. (B-D) Early neutrophil distribution in (B) blood, (C) liver / spleen, and (D) 
pelvic bone marrow compartments, at 45 minutes post re-injection of autologous 
111
In-labeled 
neutrophils on day 4. ns, non-significant across groups. (E-F) Representative longitudinal 
whole body profiles from a placebo subject and a TCZ-PMN-low subject. Radioactivity from 
pelvic bone marrow marked by black arrows. (G) Peak liver / spleen radioactivity, 
normalized to day 4 count, on days 4, 5 and 10 (45 minutes, 1 day and 6 days post re-
injection, respectively). ns, non-significant across placebo groups and across TCZ-PMN-low 
groups. (H) Peak pelvic bone marrow radioactivity, normalized to day 4 count, on days 4, 5 
and 10. # p < 0.001, placebo day 4 vs placebo day 5 and placebo day 4 vs placebo day 10; # p 
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< 0.001, placebo day 5 vs TCZ-PMN-low day 5; † p < 0.01, placebo day 10 vs TCZ-PMN-
low day 10. Placebo, n = 6; TCZ-PMN-high, n = 5; TCZ-PMN-low, n = 6. Data shown as 
mean ± SEM. 
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